Patents by Inventor Jorg Vollmer
Jorg Vollmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100285041Abstract: The invention provides an immunostimulatory nucleic acid comprising CpG motifs, and methods of use thereof in stimulating immunity.Type: ApplicationFiled: May 15, 2008Publication date: November 11, 2010Inventors: Eugen Uhlmann, Jörg Vollmer, Arthur Mertz Kreig
-
Publication number: 20100272785Abstract: Immunostimulatory polymers that contain certain sequence-dependent immunostimulatory RNA motifs and methods for the use of such immunostimulatory polymers and compositions containing such polymers are provided according to the invention. The sequence-dependent immunostimulatory RNA motifs and the polymers incorporating such motifs are potent and selective inducers of TLR7 and the TLR7-associated cytokine IFN-?.Type: ApplicationFiled: August 8, 2008Publication date: October 28, 2010Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer
-
Patent number: 7795235Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: December 17, 2008Date of Patent: September 14, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20100189772Abstract: The invention relates to methods and products for the treatment of viral infection using a combination of anti-viral agents and TLR ligands. The invention also relates to screening assays, associated products, kits, and in vitro methods.Type: ApplicationFiled: September 27, 2007Publication date: July 29, 2010Applicants: COLEY PHARMACEUTICAL GROUP, INC, COLEY PHARMACEUTICAL GMBH, COLEY PHARMACEUTICAL GROUP, LTDInventors: Jorg Vollmer, Marion Jurk, Eugen Uhlmann, Harald Debelak, Robert L. Bratzler, Alain Vicari
-
Publication number: 20100183639Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: ApplicationFiled: November 10, 2009Publication date: July 22, 2010Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Publication number: 20100144846Abstract: The invention relates to immunostimulatory RNA oligonucleotides (ORN). In particular the ORN have an immunostimulatory ORN motif directly or indirectly flanked by a 3? poly G motif and optionally a 5? poly-G motif. The invention also relates to methods including therapeutic methods and screening methods and related kits for use of the ORN.Type: ApplicationFiled: October 26, 2007Publication date: June 10, 2010Applicant: COLEY PHARMACEUTICAL GMBHInventors: Marion Jurk, Jorg Vollmer, Eugen Uhlmann
-
Patent number: 7662949Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: GrantFiled: November 22, 2006Date of Patent: February 16, 2010Assignees: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jörg Vollmer, Grayson B. Lipford
-
Patent number: 7615539Abstract: The invention relates to a nucleic acid-lipophilic conjugates and methods for modulating an immune response using the conjugates. The lipophilic moiety associated with an immunostimulatory nucleic acid.Type: GrantFiled: September 27, 2004Date of Patent: November 10, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Eugen Uhlmann, Jörg Vollmer, Arthur M. Krieg
-
Publication number: 20090191188Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.Type: ApplicationFiled: February 26, 2009Publication date: July 30, 2009Applicants: University of Iowa Research Foundation, Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Christian Schetter, Jorg Vollmer
-
Patent number: 7566703Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jörg Vollmer, Eugen Uhlmann
-
Publication number: 20090137519Abstract: The invention relates to specific C-Class semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. In particular the oligonucleotides are useful for treating allergy, such as allergic rhinitis and asthma, cancer and infectious disease, such as hepatitis B and hepatitis C.Type: ApplicationFiled: December 17, 2008Publication date: May 28, 2009Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann
-
Publication number: 20090087446Abstract: Immunostimulatory oligonucleotides, which contain a CpG immunostimulatory motif and a second motif that is capable of forming secondary structure, including duplex and higher order structures in vitro and in vivo, are disclosed. They include nucleic acids, or pharmaceutically acceptable salts thereof, having base sequences that include 5? TCGTCGTTTTCGGCGCGCGCCGT 3? (SEQ ID NO: 1), in which each C is unmethylated and 3? refers to the 3? end of the nucleic acid. The oligonucleotides activate B cells and NK cells and induce expression of type I interferon and interferon-?. The oligonucleotides are useful for treating a variety of disorders and conditions, including allergy, asthma, infection, and cancer. In addition to their use as single agents and as combination therapies, the disclosed oligonucleotides are useful as adjuvants in vaccines.Type: ApplicationFiled: August 12, 2008Publication date: April 2, 2009Inventors: JORG VOLLMER, Eugen Uhlmann, Arthur M. Krieg, Douglas C. Hanson, Ulrike Samulowitz
-
Publication number: 20080226649Abstract: Immunostimulatory compositions described as CpG-like nucleic acids are provided, including nucleic acids having immunostimulatory characteristics of CpG nucleic acid, despite certain substitutions of C, G, or C and G of the CpG dinucleotide. The substitutions can include, among others, exchange of methylated C for C, inosine for G, and ZpY for CpG, where Z is cytosine or dSpacer and Y is inosine, 2-aminopurine, nebularine, or dSpacer. Also provided are methods for inducing an immune response in a subject using the CpG-like nucleic acids. The methods are useful in the treatment of a subject that has or is at risk of developing an infectious disease, allergy, asthma, cancer, anemia, thrombocytopenia, or neutropenia.Type: ApplicationFiled: March 19, 2007Publication date: September 18, 2008Applicant: Coley Pharmaceutical GmbHInventors: Christian Schetter, Jorg Vollmer
-
Publication number: 20080045473Abstract: The present invention relates generally to immunostimulatory nucleic acids, compositions thereof and methods of using the immunostimulatory nucleic acids. In particular the invention relates to palindrome-containing immunostimulatory nucleic acids and the use of these nucleic acids in treating disease.Type: ApplicationFiled: February 15, 2007Publication date: February 21, 2008Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Eugen Uhlmann, Jorg Vollmer, Arthur Krieg, Ulrike Samulowitz, Bernhard Noll
-
Publication number: 20080009455Abstract: The invention relates to a class of short CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response. Preferably the short oligonucleotides are soft or semi-soft oligonucleotides.Type: ApplicationFiled: February 24, 2006Publication date: January 10, 2008Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Ulrike Samulowitz, Jorg Vollmer
-
Publication number: 20070224210Abstract: The invention relates to a class of soft or semi-soft CpG immunostimulatory oligonucleotides that are useful for stimulating an immune response.Type: ApplicationFiled: October 4, 2006Publication date: September 27, 2007Applicants: Coley Pharmaceutical Group, Inc., Coley Pharmaceutical GmbHInventors: Arthur Krieg, Grayson Lipford, Ulrike Samulowitz, Jorg Vollmer, Eugen Uhlmann, Marion Jurk, Robert Rankin
-
Patent number: 7271156Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.Type: GrantFiled: December 9, 2002Date of Patent: September 18, 2007Assignees: University of Iowa Research Foundation, Coley Pharmaceutical GmbHInventors: Arthur M. Krieg, Jörg Vollmer, Christian Schetter
-
Publication number: 20070142315Abstract: The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8).Type: ApplicationFiled: November 22, 2006Publication date: June 21, 2007Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Inc.Inventors: Alexandra Forsbach, Jorg Vollmer, Grayson Lipford
-
Publication number: 20070066554Abstract: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than 50% c nucleotides. These immunostimulatory nucleic acids function in a similar manner to nucleic acids containing CpG motifs. The invention also encompasses preferred CpG nucleic acids.Type: ApplicationFiled: August 18, 2006Publication date: March 22, 2007Applicants: Coley Pharmaceutical GmbH, University of Iowa Research FoundationInventors: Arthur Krieg, Christian Schetter, Jorg Vollmer
-
Publication number: 20060246035Abstract: The invention provides methods for identifying and treating subjects having hepatitis C infections. In some instances, the subjects are those that are non-responsive to non-CpG therapy. Preferably, the subjects are treated with C class CpG immunostimulatory nucleic acids having a semi-soft backbone.Type: ApplicationFiled: October 29, 2003Publication date: November 2, 2006Applicants: Coley Pharmaceutical GmbH, Coley Pharmaceutical Group, Ltd.Inventors: Navneet Ahluwalia, Susan Efler, Heather Davis, Jorg Vollmer